Find Funding Opportunities

Returning 185 results

BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00 Independent Clinical Trial Not Allowed)

PAR
Friday, June 1, 2018
Saturday, May 8, 2021
K99/R00
PAR-18-814

Funding Opportunity Purpose

The NINDS, with other NIH Institutes and Centers participating in the BRAIN Initiative, intends to publish "BRAIN Initiative Advanced Postdoctoral Career Transition Award to Promote Diversity (K99/R00)." The program is designed to increase biomedical research workforce diversity and foster a strong cohort of new, highly skilled and well trained, NIH-supported, independent investigators from underrepresented groups working in research areas supported by the BRAIN Initiative, as highlighted in BRAIN 2025: A Scientific Vision. It is designed to facilitate a timely transition of outstanding postdoctoral researchers with a research and/or clinical doctorate degree from mentored, postdoctoral research positions to independent, tenure-track or equivalent faculty positions. This Notice is being provided to allow potential applicants sufficient time to develop meaningful mentoring teams and responsive projects. The FOA is expected to be published in April 2018 with an expected application due date in June 2018. This FOA will utilize the K99/R00 funding activity. Details of the planned FOA are provided below. Research Initiative Details The BRAIN Initiative K99/R00 award is intended for women and members of underrepresented groups who are working in research areas supported by the BRAIN Initiative, who have no more than five years of postdoctoral research experience, and who require at least 12 months of mentored research training and career development (K99 phase) before transitioning to the independent research (R00) phase of the program. All research areas within the BRAIN Initiative are encouraged (including but not limited to engineering, computer science, statistics, mathematics, physics, chemistry and neuroethics). Eligible individuals for this program will be U.S. citizens or permanent residents who fall in at least one of three defined categories: 1) women, 2) individuals from underrepresented racial and ethnic groups as defined in the Notice of NIH's Inter

BRAIN Initiative: Exploratory Team-Research BRAIN Circuit Programs - eTeamBCP (U01 Clinical Trial Not Allowed)

RFA
Thursday, May 17, 2018
Tuesday, June 11, 2019
U01
RFA-NS-18-029

Funding Opportunity Purpose

The purpose of this FOA is to promote the integration of experimental, analytic, and theoretical capabilities for large-scale analysis of neural systems and circuits. This FOA seeks applications for exploratory research studies that use new and emerging methods for large scale recording and manipulation of neural circuits across multiple brain regions. Applications should propose to elucidate the contributions of dynamic circuit activity to a specific behavioral or neural system. Applications should seek to understand circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Studies should incorporate rich information on cell-types, on circuit functionality and connectivity, and should be performed in conjunction with sophisticated analysis of complex, ethologically relevant behaviors. Applications should propose teams of investigators that seek to cross boundaries of interdisciplinary collaboration by bridging fields and linking theory and data analysis to experimental design. Exploratory studies supported by this FOA are intended to develop experimental capabilities and quantitative, theoretical frameworks in preparation for a future competition for larger-scale, multi-component, Team-Research BRAIN Circuit Programs (U19).

NINDS Research Education Opportunities (R25 Clinical Trial Not Allowed)

PAR
Friday, May 11, 2018
Friday, August 28, 2020
R25
PAR-18-782

Funding Opportunity Purpose

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NINDS R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs.

BRAIN Initiative: Development and Validation of Novel Tools to Probe Cell-Specific and Circuit-Specific Processes in the Brain (R01 Clinical Trial Not Allowed)

RFA
Thursday, May 3, 2018
Thursday, September 10, 2020
R01
RFA-MH-19-136

Funding Opportunity Purpose

The purpose of this Brain Research through Advancing Innovative Neurotechnologies (BRAIN) Initiative is to encourage applications that will develop and validate novel tools to facilitate the detailed analysis of complex circuits and provide insights into cellular interactions that underlie brain function. The new tools and technologies should inform and/or exploit cell-type and/or circuit-level specificity. Plans for validating the utility of the tool/technology will be an essential feature of a successful application. The development of new genetic and non-genetic tools for delivering genes, proteins and chemicals to cells of interest or approaches that are expected to target specific cell types and/or circuits in the nervous system with greater precision and sensitivity than currently established methods are encouraged. Tools that can be used in a number of species/model organisms rather than those restricted to a single species are highly desired. Applications that provide approaches that break through existing technical barriers to substantially improve current capabilities are highly encouraged.

BRAIN Initiative: Targeted BRAIN Circuits Projects- TargetedBCP (R01 Clinical Trial Not Allowed)

RFA
Thursday, April 19, 2018
Wednesday, November 11, 2020
R01
RFA-NS-18-030

Funding Opportunity Purpose

This FOA solicits applications for research projects that use innovative, methodologically-integrated approaches to understand how circuit activity gives rise to mental experience and behavior. The goal is to support projects that can realize a meaningful outcome within 5 years. Applications should address circuit function in the context of specific neural systems such as sensation, perception, attention, reasoning, intention, decision-making, emotion, navigation, communication or homeostasis. Projects should link theory and data analysis to experimental design and should produce predictive models as deliverables. Projects should aim to improve the understanding of circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating dynamic patterns of neural activity. Projects can use non-human and human species, and applications should explain how the selected species offers ideal conditions for revealing general principles about the circuit basis of a specific behavior.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

PAR
Thursday, April 19, 2018
Translational Research
Saturday, May 8, 2021
R61/R33
PAR-18-763

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages the development and validation of: 1) animal models and human tissue ex vivo systems that recapitulate the phenotypic and physiologic characteristics of a defined neurological disorder and/or 2) clinically feasible pharmacodynamic markers for therapeutics designed to treat neurological disease. The goal of this FOA is to promote a significant improvement in the translational relevance of animal models, ex vivo systems, and pharmacodynamic markers that will be utilized to facilitate the development of neurotherapeutics. Ideally, models, model systems and pharmacodynamic markers proposed in applications for this FOA would have the potential to provide feasible and meaningful assessments of efficacy following therapeutic intervention that would be applicable in both preclinical and clinical settings. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) focused on enabling the exploratory and early stages of drug discovery.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Assay Development and Neurotherapeutic Agent Identification (R61/R33 Clinical Trial Not Allowed)

PAR
Thursday, April 19, 2018
Translational Research
Saturday, May 8, 2021
R61/R33
PAR-18-762

Funding Opportunity Purpose

This funding opportunity announcement (FOA) encourages research grant applications to develop in vitro and/or ex vivo assays and conduct iterative screening efforts to identify and characterize potential therapeutic agents for neurological disorders. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics (CREATE Bio) program for biologics, biotechnology products, the Blueprint Neurotherapeutics Network (BPN) for small molecules, or other translational programs.

Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)

PAR
Thursday, April 19, 2018
Translational Research
Saturday, May 8, 2021
R61/R33
PAR-18-761

Funding Opportunity Purpose

This FOA provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological disorders that fall under the NINDS mission. Therapeutic agents may include but are not limited to small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the NINDS Cooperative Research to Enable and Advance Translational Enterprises for Biologics program (CREATE Bio) program for biologics, biotechnology products, Blueprint Neurotherapeutics Network for small molecules, or other translational programs.

Small Research Grants for Establishing Basic Science-Clinical Collaborations to Understand Structural Birth Defects (R03 - Clinical Trial Not Allowed)

PAR
Friday, March 30, 2018
Sunday, September 8, 2019
R03
PAR-18-734

Funding Opportunity Purpose

The purpose of this funding opportunity announcement (FOA) is to promote initial establishment of basic science-clinical collaborations by providing small grants to teams of basic scientists, physician scientists, and/or clinicians. These interdisciplinary teams may include but are not limited to the following: developmental biologists, cell biologists, geneticists, genomicists, physician scientists including individuals with DVM/VMD degrees, clinicians, epidemiologists, biostatisticians, and/or bioinformaticists.

Countermeasures Against Chemical Threats (CounterACT) Exploratory/Developmental Projects in Translational Research (R21 Clinical Trial Not Allowed)

PAR
Wednesday, March 28, 2018
Wednesday, May 27, 2020
R21
PAR-18-721

Funding Opportunity Purpose

This Funding Opportunity Announcement (FOA) encourages applications for Countermeasures Against Chemical Threats (CounterACT) exploratory/developmental translational research (R21). The mission of the CounterACT program is to foster and support research and development of new and improved therapeutics to mitigate the health effects of chemical threats. Chemical threats are toxic chemicals that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include traditional chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The scope of the research includes basic toxicological research on the chemical threat for the purpose of target and therapeutic hit identification, hit validation, lead optimization, and demonstration of in vivo ADME/Tox and efficacy. Projects supported by this FOA are expected to generate preliminary data that would facilitate the development of competitive applications for more extensive support from the NIH CounterACT Cooperative Agreement programs or other related initiatives.

Pages